Brought to you by 
Myogen, Novartis Institutes in cardiovascular drug deal
02 May 2006
Executive Summary
Myogen (small-molecule cardiovascular therapeutics) and the Novartis Institutes for Biomedical Research (an affiliate of Novartis AG) will collaborate on the discovery and development of new histone deacetylase inhibitors to treat cardiac hypertrophy and heart failure.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Myogen, Novartis Institutes in cardiovascular drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice